Artificial intelligence (AI) is rapidly emerging as a game-changer in the global pharmaceutical landscape, and India is actively embracing this transformation.
The Department of Pharmaceuticals recently underscored the growing importance of AI in reshaping drug discovery, development, and regulatory processes during a high-level webinar held under Sādhana Saptah 2026.
The webinar, titled “AI and Emerging Technologies in Pharmaceuticals and Regulations,” highlighted how AI is revolutionising the entire drug development lifecycle. From identifying potential drug candidates in early research to monitoring drug safety after market approval, AI is enabling faster, more efficient, and data-driven processes.
Experts noted that AI is helping pharmaceutical companies significantly cut down the traditionally long timelines and high costs associated with drug development, which can often take over a decade globally.
Addressing the session, Prof. Manoj Kumar from the National Institute of Pharmaceutical Education and Research Mohali explained how AI tools are transforming early-stage research.
These advancements are particularly significant as global pharmaceutical R&D spending continues to rise, with companies increasingly relying on digital tools to enhance productivity.
The discussion also focused on the growing adoption of AI in pre-clinical and clinical phases. AI-driven tools are now being used for:
AI enables precise patient stratification, ensuring that clinical trials are more targeted and effective. This improves the accuracy of results and enhances the likelihood of successful drug approvals.
In the regulatory domain, AI-powered decision support systems are becoming increasingly important. These tools assist in:
The webinar highlighted that adopting AI in regulatory systems can significantly improve efficiency while maintaining high standards of safety and compliance.
Officials stressed the importance of strengthening institutional capabilities within government bodies to effectively integrate AI into policymaking and regulatory oversight. This aligns with broader governance reforms under Mission Karmayogi.
Participants were also introduced to several advanced AI applications, including:
These innovations are accelerating pharmaceutical breakthroughs and opening new pathways for treating complex diseases.
The Department of Pharmaceuticals emphasized that integrating AI across the value chain will enhance India’s position as a global pharmaceutical hub. India already accounts for a significant share of global generic drug supply, and AI adoption is expected to further boost competitiveness.
By reducing development costs and timelines, AI can also help improve access to affordable and effective medicines, particularly in developing countries.
The webinar was part of Sādhana Saptah 2026, a nationwide programme aimed at enhancing governance and administrative efficiency. Scheduled from April 2 to April 8, the initiative brings together ministries, state governments, and training institutions.
Under the broader framework of Mission Karmayogi, the programme focuses on:
The integration of artificial intelligence into the pharmaceutical sector marks a transformative shift that could redefine how drugs are discovered, tested, and regulated. As highlighted by the Department of Pharmaceuticals, AI-driven innovations are not only improving efficiency and accuracy but also paving the way for faster access to life-saving medicines. With initiatives like Sādhana Saptah 2026 and Mission Karmayogi, India is positioning itself at the forefront of this technological revolution, strengthening both its healthcare ecosystem and global pharmaceutical leadership.